Literature DB >> 26514853

Antibacterial antibodies gain traction.

Chris Morrison.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26514853     DOI： 10.1038/nrd4770

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  15 in total

1.  A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.

Authors:  Heather K Kroh; Ramyavardhanee Chandrasekaran; Zhifen Zhang; Kim Rosenthal; Rob Woods; Xiaofang Jin; Andrew C Nyborg; G Jonah Rainey; Paul Warrener; Roman A Melnyk; Benjamin W Spiller; D Borden Lacy
Journal:  J Biol Chem       Date:  2017-11-27       Impact factor: 5.157

2.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

3.  Fresh from the biotech pipeline-2016.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2017-01-30       Impact factor: 54.908

4.  Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In Vivo.

Authors:  Ellen K Wagner; Xianzhe Wang; Andre Bui; Jennifer A Maynard
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

Review 5.  Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.

Authors:  Amelia N Deitchman; M Tobias Heinrichs; Vipada Khaowroongrueng; Satyawan B Jadhav; Hartmut Derendorf
Journal:  AAPS J       Date:  2016-12-09       Impact factor: 4.009

6.  Vaccines for Healthcare-associated Infections: Promise and Challenge.

Authors:  Jane M Knisely; Baoying Liu; Ryan T Ranallo; Lanling Zou
Journal:  Clin Infect Dis       Date:  2016-05-20       Impact factor: 9.079

7.  Comparative genome-scale modelling of Staphylococcus aureus strains identifies strain-specific metabolic capabilities linked to pathogenicity.

Authors:  Emanuele Bosi; Jonathan M Monk; Ramy K Aziz; Marco Fondi; Victor Nizet; Bernhard Ø Palsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-10       Impact factor: 11.205

Review 8.  An update on antibody-based immunotherapies for Clostridium difficile infection.

Authors:  Greg Hussack; Jamshid Tanha
Journal:  Clin Exp Gastroenterol       Date:  2016-08-01

9.  Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.

Authors:  C Tkaczyk; M M Hamilton; A Sadowska; Y Shi; C S Chang; P Chowdhury; R Buonapane; X Xiao; P Warrener; J Mediavilla; B Kreiswirth; J Suzich; C K Stover; B R Sellman
Journal:  MBio       Date:  2016-06-28       Impact factor: 7.867

10.  Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody.

Authors:  Traian Sulea; Greg Hussack; Shannon Ryan; Jamshid Tanha; Enrico O Purisima
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.